Exocrine Pancreatic Insufficiency Market to Register Sustainable Growth During the Forecast Period – DelveInsight | Key Companies – First Wave BioPharma, Repha, Adare, Janssen, Solvay, Synspira 1
Exocrine Pancreatic Insufficiency Market to Register Sustainable Growth During the Forecast Period - DelveInsight | Key Companies - First Wave BioPharma, Repha, Adare, Janssen, Solvay, Synspira
Delveinsight Business Research LLP
As per DelveInsight, the Exocrine Pancreatic Insufficiency Market size in the 7MM was found to be USD 2,500 Million in 2021. The market is expected to grow immensely in the coming years owing to the rising prevalent population in the 7MM and the launch of emerging therapies.

DelveInsight’s “Exocrine Pancreatic Insufficiency Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Exocrine Pancreatic Insufficiency market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Exocrine Pancreatic Insufficiency market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Exocrine Pancreatic Insufficiency Market

Exocrine Pancreatic Insufficiency: An Overview

Exocrine Pancreatic Insufficiency is frequently an unrecognized consequence of benign and malignant pancreatic disease, leading to various consequences such as abdominal discomfort, steatorrhea, malnutrition, sarcopenia, osteoporosis, weight loss, reduced quality of life, and diminished survival.

Despite these rather severe outcomes, the diagnosis and management of Exocrine Pancreatic Insufficiency (EPI) are suboptimal, underscoring the importance of awareness in high-risk patients, appropriate use of diagnostic testing, and understanding of treatment goals and strategies. However, current literature suggests that patients who are at high risk of developing Exocrine Pancreatic Insufficiency (EPI) do not undergo testing or are not treated with adequate dosages.

Exocrine Pancreatic Insufficiency Market Key Facts

  • In the 7MM, the highest prevalence of Exocrine Pancreatic Insufficiency was observed in the United States, with 176,112 cases in 2021, which is expected to increase during the forecast period (2022–2032).

  • The Exocrine Pancreatic Insufficiency market is expected to grow by the factors like the increase in the prevalent pool, the expected entry of emerging therapies with novel targets and attractive pricing, and more penetration of the therapies in the 7MM markets.

Exocrine Pancreatic Insufficiency Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Exocrine Pancreatic Insufficiency market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Exocrine Pancreatic Insufficiency market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Exocrine Pancreatic Insufficiency Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Exocrine Pancreatic Insufficiency Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Exocrine Pancreatic Insufficiency market or expected to get launched during the study period. The analysis covers the Exocrine Pancreatic Insufficiency market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Exocrine Pancreatic Insufficiency Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Exocrine Pancreatic Insufficiency Market Will Evolve by 2032 @


Exocrine Pancreatic Insufficiency Therapeutics Analysis

The diagnosis, prognosis, and management of Exocrine Pancreatic Insufficiency continue to be challenging in current practice. This is related to an incomplete understanding of the pathophysiology of the disease and its associated disorders and the complexity of initiating factors. However, the companies are currently working on novel therapies to effectively manage Exocrine Pancreatic Insufficiency (EPI).

Some of the key companies in the Exocrine Pancreatic Insufficiency (EPI) Market include:

  • Repha GmbH

  • Adare Pharmaceuticals

  • Janssen Pharmaceuticals

  • Solvay Pharmaceuticals

  • Synspira Therapeutics

  • AzurRx Biopharma

And many others

Exocrine Pancreatic Insufficiency (EPI) therapies covered in the report include:

  • MS1819

  • SNSP003

  • Creon

  • Pancreaze

  • Zenpep

  • Nortase

And many more

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More – 


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Exocrine Pancreatic Insufficiency Competitive Intelligence Analysis

4. Exocrine Pancreatic Insufficiency Market Overview at a Glance

5. Exocrine Pancreatic Insufficiency Disease Background and Overview

6. Exocrine Pancreatic Insufficiency Patient Journey

7. Exocrine Pancreatic Insufficiency Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Exocrine Pancreatic Insufficiency Treatment Algorithm, Current Treatment, and Medical Practices

9. Exocrine Pancreatic Insufficiency Unmet Needs

10. Key Endpoints of Exocrine Pancreatic Insufficiency Treatment

11. Exocrine Pancreatic Insufficiency Marketed Products

12. Exocrine Pancreatic Insufficiency Emerging Drugs and Latest Therapeutic Advances

13. Exocrine Pancreatic Insufficiency Seven Major Market Analysis

14. Attribute Analysis

15. Exocrine Pancreatic Insufficiency Market Outlook (In US, EU5, and Japan)

16. Exocrine Pancreatic Insufficiency Access and Reimbursement Overview

17. KOL Views on the Exocrine Pancreatic Insufficiency Market

18. Exocrine Pancreatic Insufficiency Market Drivers

19. Exocrine Pancreatic Insufficiency Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Exocrine Pancreatic Insufficiency (EPI) Pipeline Insights

DelveInsight’s “Exocrine Pancreatic Insufficiency (EPI) Pipeline Insights, 2022” report outlays comprehensive insights into the present clinical development scenario and growth prospects across the Exocrine Pancreatic Insufficiency therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Leave a Reply

Your email address will not be published. Required fields are marked *